Skip to main content

Table 4 Annual results of universal and targeted RV vaccination compared to no vaccination under base-case assumptions

From: Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination

 

RV disease burden (95% CI)a

  RV disease costsa(€ million)

Vaccination costs (€ million)

 

Disease episodes (x1000)

Hospitalizationsb

Fatal cases

QALY’s lost (undiscounted)

Direct healthcare costs (undiscounted)

Societal costs (undiscounted)

(undiscounted)

No vaccination

74.1(57.8; 90.0)

4,870 (4,310; 5,430)

6.5 (3.2; 11.0)

257 (136; 422)

11.9 (10.5; 13.3)

18.2 (16.2; 20.3)

-

Targeted RV vaccination

       

RV1

67.3 (51.3; 82.4)

4,370 (3,890; 4,870)

0.7(0.2; 1.6)

119 (79; 177)

10.5 (9.3; 11.8)

16.4 (14.6; 18.2)

1.5

 Percent reduction

8%

10%

89%

54%

12%

10%

 

RV5

67.4 (51.5; 82.7)

4,384 (3,892; 4,870)

0.8 (0.3; 1.7)

121 (80; 184)

10.6 (9.4; 11.8)

16.4 (14.6; 18.2)

1.6

 Percent reduction

8%

10%

88%

53%

11%

10%

 

Universal RV vaccination

       

RV1

40.6 (30.1; 51.2)

1,370 (1,150; 1,650)

0.4 (0.2; 0.8)

60 (42; 81)

3.4 (2 8; 4 1)

5.9 (5.0; 6.9)

15.2

 Percent reduction

45%

72%

94%

77%

71%

67%

 

RV5

42.6 (31.7; 53.6)

1,440 (1,210; 1,710)

0.5(0.2; 0.9)

66 (45; 91)

3.6 (3.1; 4.3)

6.3 (5.3; 7.3)

16.7

 Percent reduction

43%

70%

92%

75%

70%

65%

 
  1. aResults reflect those five years and more after initial implementation of a vaccination strategy when steady state is reached; bincluding nosocomial infections. CI:confidence interval; QALY:quality-adjusted life year; RV: rotavirus.